Special: Warren Buffett Was WRONG on This One… Time for YOU to Profit!



CTRV: ContraVir Pharmaceuticals is a Buy

The current rating for CTRV is 100, which is 100% above its historic median rating of 50. This indicates lower risk than normal.

The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.